Drug intelligence / Profile preview

vancomycin + gentamicin + rifampin

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination antibiotic therapy used primarily for treating serious staphylococcal infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci. This combination is often used for infective endocarditis, prosthetic valve infections, and other biofilm-associated infections. The combination shows varying efficacy depending on the specific infection type and patient population.

Targets

rpoB (DNA-directed RNA polymerase subunit beta)30S A-site (Bacterial ribosomal 30S A-site)D-Ala-D-Ala (D-Ala-D-Ala terminus)

Beyond the preview

Go deeper on vancomycin + gentamicin + rifampin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vancomycin + gentamicin + rifampin.

Explore the full profile